Document is current

Article History

Received: 14 January 2022

Accepted: 25 June 2022

First Online: 9 July 2022

Declaration

:

: DV, RH, ML and JP declare no financial interests.KBM is founder and CEO of Cercare Medical and owns shares in the company. The Ethics Committee of EANM considered the risk of biased statements of being low.PL reports, within and outside the submitted work, grants/sponsored research agreements from Radiomics SA of which he is the founder, from ptTheragnostic/DNAmito and from Health Innovation Ventures. He received an advisor/presenter fee and/or reimbursement of travel costs/consultancy fee and/or in-kind manpower contribution from Radiomics SA, BHV, Merck, Varian, Elekta and ptTheragnostic. He has minority shares in the company Radiomics SA and MedC2. He is co-inventor of two issued patents with royalties on radiomics (PCT/NL2014/050248, PCT/NL2014/050728) licensed to Radiomics SA and one issue patent on mtDNA (PCT/EP2014/059089) licensed to ptTheragnostic/DNAmito and co-inventor of 3 non-patented invention (softwares) licensed to ptTheragnostic/DNAmito, Radiomics SA and Health Innovation Ventures plus 3 non-issues, non-licensed patents on deep learning-radiomics and LSRT (no. 17123816, PCT/NL/2020/050794, no. 2025017). He confirms that none of the above entities or funding was involved in the preparation of this paper. The Ethics Committee consider the risk of biased statements of being low.KS received public support for research, but also from Novartis. CR reports support on amyloidosis research, partially from commercial entities. In both cases, the risk of biased statements is considered of being low.